Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, taking advantage of the early data on offer from the country’s faster and more lightly regulated trials.
Large pharmaceutical groups including GSK, Merck and AstraZeneca have each signed $1bn-plus agreements in the past two years to buy the rights to develop and sell Chinese drugs outside the country.
Meanwhile, investors including Forbion, Bain Life Sciences and General Atlantic have ploughed hundreds of millions of dollars into new biotechs that will develop Chinese assets for western markets, hoping to be bought by major drugmakers.
您已閱讀9%（662字），剩餘91%（7022字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。
